Clinical Trial Update: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update assesses venetoclax with polatuzumab vedotin, rituximab, and CHP in untreated BCL-2 IHC-positive diffuse large B-cell lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Adriamycin (doxorubicin)
• Cytoxan (cyclophosphamide)
• Deltasone (prednisone)
• Polivy (polatuzumab vedotin)
• Rituxan (rituximab)
• Venclexta (venetoclax)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphoma, Large B-Cell, Diffuse | Phase 1 | Status: TERMINATED